MARKET

PULM

PULM

Pulmatrix
NASDAQ
1.750
+0.130
+8.02%
After Hours: 1.640 -0.11 -6.29% 17:28 03/28 EDT
OPEN
1.650
PREV CLOSE
1.620
HIGH
1.850
LOW
1.560
VOLUME
38.38K
TURNOVER
0
52 WEEK HIGH
3.150
52 WEEK LOW
1.550
MARKET CAP
6.39M
P/E (TTM)
-0.3929
1D
5D
1M
3M
1Y
5Y
Pulmatrix GAAP EPS of -$3.87, revenue of $7.3M
Seeking Alpha · 3h ago
Press Release: Pulmatrix Announces Year-End and -2-
Pulmatrix is a clinical-stage biopharmaceutical company focused on the development of novel inhaled therapeutic products. Pulmatrix's product pipeline includes treatments for central nervous system disorders and serious lung diseases. The company's net loss for the quarter was $18,836.
Dow Jones · 8h ago
Press Release: Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
Pulmatrix Announces Year-End and Q4 2023 financial results and Provides Corporate Update. $19.2 million cash and cash equivalents provide projected cash runway into Q1 2026. Pulmatrix is a clinical-stage company developing inhaled therapies to address serious central nervous system and pulmonary disease. The company has wind down of the PUR1900 Phase 2b study.
Dow Jones · 8h ago
Weekly Report: what happened at PULM last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at PULM last week (0311-0315)?
Weekly Report · 03/18 09:46
Pulmatrix Shifts to Outsourced CMO Model, Terminates Executive
Pulmatrix terminated its Chief Medical Officer, Dr. Margaret Wasilewski, as part of a move to an outsourced, part-time CMO model. The decision was not due to any disagreements on company operations or practices. PULM will receive severance benefits.
TipRanks · 03/13 10:12
Weekly Report: what happened at PULM last week (0304-0308)?
Weekly Report · 03/11 09:45
Pulmatrix to Present at Investor Conferences, Limits Updates
TipRanks · 03/04 21:24
More
About PULM
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing inhaled therapies to address serious pulmonary diseases and central nervous system (CNS) disorders using its patented inhaled small particles easily respirable and emitted (iSPERSE) technology. Its inhaled therapeutic products based on its dry powder delivery technology, namely iSPERSE enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways. Its iSPERSE’s lead development program, PUR1900 is its inhaled formulation of itraconazole, an anti-fungal drug commercially available as an oral drug, which it is developing to treat and prevent pulmonary fungal infections. Its pipeline also includes PUR3100 for the treatment of acute migraine, and PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).

Webull offers Pulmatrix Inc stock information, including NASDAQ: PULM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PULM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PULM stock methods without spending real money on the virtual paper trading platform.